Denise M. Wolf, MD, PhD, University of California, San Fransisco, CA, shares an overview of the Phase II I-SPY2 (NCT01042379) trial designed to improve outcomes in patients with high-risk breast cancer patients. The trial is examining novel agents in the neoadjuvant setting in combination with standard chemotherapy using an adaptive framework to match treatments with the most responsive subtype of breast cancer, considering patient characteristics and immune host interactions. By rapidly testing various experimental agents, the study aims to identify the most effective treatments for different subsets of breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.